Application of Products Produced Through Biotechnology in Infectious Diseases

Abstract

Get full access to this article

View all access options for this article.

References

Fauci AS , Rosenberg SA , Sherwin SA , et al: Immunomodulators in clinical medicine. Ann Intern Med 106:421-433,1987

Dinarello CA : Interleukin-1. Rev Infect Dis 6:51-95, 1984

Smith KA : T-cell growth factor. Immunol Rev 51:337-357, 1980

Rook AH , Masur H. , Lane HC , et al: Interleukin-2 enhances the depressed natural killer and cytomegalovirus specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. J Clin Invest 72:398-403, 1983

Lê thi Bich-Thuy , Fauci AS : Recombinant interleukin 2 and gamma interferon act synergistically on distinct steps of in vitro terminal human B cell maturation . J Clin Invest 77:1173-1179, 1986

Kehrl JH , Muraguchi A. , Butler JL , et al: Human B cell activation, proliferation and differentiation. Immunol Rev 78:75-96,1984

Falkoff Rjm , Muraguchi A. , Hong J-X. , et al: The effects of interleukin 1 on human B cell activation and proliferation. J Immunol 131:801-805, 1983

Matsushima K. , Taguchi M. , Kovacs EJ , et al: Intracellular localization of human monocyte associated interleukin 1 (IL-1) activity and release of biologically active IL-1 from monocytes by trypsin and plasma. J Immunol 136:2883-2991, 1986

Pennington JE : Immunotherapy for infectious diseases. West J Med 152:401-405, 1990

10.

Harkonen S. , Scannon P. , Mischak RP , et al: Phase I study of a murine monoclonal anti-lipid A antibody in bacteremic and nonbacteremic patients. Antimicrob Agents Chemother 32:710-716, 1988

11.

Ziegler EJ , McCutchan JA , Fierer J. , et al: Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 307:1225-1230, 1982

12.

Wedel NI , Gorelick KJ , Saria EA , et al: Pharmacokinetics and safety of antiendotoxin antibody E5 (E5) in normal subjects. Crit Care Med 18:s212, 1990 (abstr)

13.

Gorelick KJ , Wedel NI , Kunz AY , et al: E5 antiendotoxin antibody in gram-negative sepsis: Report of a phase II study. Crit Care Med 18:s261, 1990 (abstr)

14.

Gorelick KJ , Schein Rmh , MacIntyre NR , et al: Multicenter trial of antiendotoxin antibody E5 in the treatment of gram-negative sepsis (GNS). Crit Care Med 18:s253, 1990 (abstr)

15.

Kunz AY , Wedel NI , Saria EA , et al: Human anti-murine antibody (HAMA) response to murine monoclonal antiendotoxin antibodies: Significance in the treatment of gram-negative sepsis (GNS). Crit Care Med 18: s212, 1990 (abstr)

16.

Fisher CJ Jr , Zimmerman J. , Khazaeli MB , et al: Initial evaluation of human monoclonal anti-lipid A antibody (HA-1A) in patients with sepsis syndrome . Crit Care Med 18:1311-1315, 1990

17.

b. Ziegler EJ , Fisher CJ Jr , Sprung CL , et al: Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: A randomized, double-blind, placebo-controlled trial. N Engl J Med 324:429-436,1991

18.

Stoll BJ , Pollack M. , Young LS , et al: Functionally active monoclonal antibody that recognizes an epitope on the O side chain of Pseudomonas aeruginosa immunotype-1 lipopolysaccharide . Infect Immun 53:656-662,1986

19.

Hector RF , Collins MS , Pennington JE : Treatment of experimental Pseudomonas aeruginosa pneumonia with a human IgM monoclonal antibody. J Infect Dis 160:483-439, 1989

20.

Pennington JE : Newer uses of intravenous immunoglobulins as anti-infective agents. Antimicrob Agents Chemother 34:1463-1466, 1990

21.

Griffiths SD , Galvani DW , Cawley JC : The Interferons, in Hamblin TJ (ed): Immunotherapy of Disease. Boston, MA, Kluwer Academic, 1989, pp 43-69

22.

Tyrrell Daj : Interferons and their clinical value. Rev Infect Dis 9:243-249,1987

23.

Gall SA , Hughes CE , Trofatter K. : Interferon for the therapy of condyloma acuminatum. Am J Obstet Gynecol 153:157-163,1985

24.

Eron LJ , Judson F. , Tucker S. , et al: Interferon therapy for condylomata acuminata. N Engl J Med 315:1059-1064, 1986

25.

Kraus SJ , Stone KM : Management of genital infection caused by human papillomavirus. Rev Infect Dis 12:s620-632,1990 (suppl 6)

26.

Greenberg HB , Pollard RB , Lutwick LI , et al: Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med 295:517-522, 1976

27.

Perrillo RP , Regenstein FG , Peters MG , et al: Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis. A randomized, controlled trial. Ann Intern Med 109:95-100, 1988

28.

Porres JC , Carreno V. , Mora I. , et al: Different doses of recombinant alpha interferon in the treatment of chronic hepatitis B patients without antibodies against the human immunodeficiency virus. Hepatogastroenterology 35:300-303, 1988

29.

Williams SJ , Craig PI , Cooksley Wge , et al: Randomised controlled trial of recombinant human interferon-alpha A for chronic active hepatitis B. Aust N Z J Med 20:9-19, 1990

30.

Alexander Gjm , Brahm J. , Fagan EA , et al: Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection. Lancet 2:66-69, 1987

31.

Brook MG , McDonald JA , Karayiannis P. , et al: Randomised controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: Factors that influence response. Gut 30:1116-1122, 1989

32.

Hess G. , Rossol S. , Voth R. , et al: Treatment of patients with chronic type B hepatitis and concurrent human immunodeficiency virus infection with a combination of interferon alpha and azidothymidine: A pilot study. Digestion 43:56-59, 1989

33.

Hayashi J. , Noguchi A. , Nakashima K. , et al: Human lymphoblastoid and fibroblast interferon in the treatment of chronic hepatitis B. Clin Ther 12:12-21, 1990

34.

Porres JC , Mora I. , Gutiez J. , et al: Antiviral effect of recombinant gamma interferon in chronic hepatitis B virus infection: A pilot study. Hepatogastroenterology 35:5-9, 1988

35.

Davis GL , Balart LA , Schiff ER , et al: Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 321:1501-1506,1989

36.

Alter MJ , Sampliner RE : Hepatitis C. And miles to go before we sleep. N Engl J Med 321:1538-1540, 1989 (editorial)

37.

DiBisceglie AM , Martin P. , Kassianides C. , et al: Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial . N Engl J Med 321:1506-1510, 1989

38.

Schvarcz R. , Weiland O. , Wejstal R. , et al: A randomized controlled open study of interferon alpha-2b treatment of chronic non-A, non-B posttransfusion hepatitis: No correlation of outcome to presence of hepatitis C virus antibodies. Scand J Infect Dis 21:617-625, 1989

39.

Koff RS : Interferon treatment of chronic non-A, non-B (HCV) hepatitis: The saga continues . Gastroenterology 98:1384-1386, 1990

40.

Krown SE : Approaches to interferon combination therapy in the treatment of AIDS . Semin Oncol 17:11-15, 1990 (suppl 1)

41.

Lane HC , Davey V. , Kovacs JA , et al: Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial. Ann Intern Med 112:805-811, 1990

42.

Winston DJ , Eron LJ , Ho M. , et al: Recombinant interferon alpha-2a for treatment of herpes zoster in immunosuppressed patients with cancer. Am J Med 85:147-151, 1988

43.

Hayden FG , Albrecht JK , Kaiser DL , et al: Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon. N Engl J Med 314:71-75, 1986

44.

Douglas RM , Moore BW , Miles HB , et al: Prophylactic efficacy of intranasal alpha 2-interferon against rhinovirus infections in the family setting. N Engl J Med 314:65-70, 1986

45.

Kahn JO , Allan JD , Hodges TL , et al: The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS related-complex: A phase I study. Ann Intern Med 112:254-261, 1990

46.

Capon DJ , Chamow SM , Mordenti J. , et al: Designing CD4 immunoadhesins for AIDS therapy. Nature 337:525-531, 1989

47.

Tramont EC , Redfield RR : Soluble CD4: The first step. Ann Intern Med 112:241-242, 1990 (editorial)

48.

Schooley RT , Merigan TC , Gaut P. , et al: Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex: A phase I-II escalating dosage trial. Ann Intern Med 112:247-253, 1990

49.

Hirsch MS : Chemotherapy of human immunodeficiency virus infections: Current practice and future prospects. J Infect Dis 161:845-857, 1990

50.

Hopwood DA : Antibiotics: Opportunities for genetic manipulation. Philos-Trans R Soc Lond B324:549-562, 1989 49. Weisbart RH , Gasson JC , Golde DW : Colony-stimulating factors and host defense . Ann Intern Med 110:297-303, 1989

51.

Jimenez JJ , Vargas-Cuba R. , Temple JD : The role of recombinant hematopoietic growth factors in blood diseases . Adv Intern Med 35:393-414, 1990

52.

Antman KS , Griffin JD , Elias A. , et al: Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 319:593-598,1988

53.

Herrmann F. , Schulz G. , Wieser M. , et al: Effect of granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy . Am J Med 88:619-624, 1990

54.

Hammond WP IV , Price TH , Souza LM , et al: Treatment of cyclic neutropenia with granulocyte colony-stimulating factor. N Engl J Med 320:1306-1311, 1989

55.

Ganser A. , Ottmann OG , Erdmann H. , et al: The effect of recombinant human granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity in chronic severe neutropenia . Ann Intern Med 111:887-892, 1989

56.

Groopman JE , Mitsuyasu RT , DeLeo MJ , et al: Effect of recombinant human granulocyte-macrophage colony stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. N Engl J Med 317:593-598, 1987

57.

Groopman JE : Status of colony stimulating factors in cancer and AIDS. Semin Oncol 17:31-37, 1990 (suppl 1)

58.

Ciobanu N. , Welte K. , Kruger G. , et al: Defective T-cell response to PHA and mitogenic monoclonal antibodies in male homosexuals with acquired immunodeficiency syndrome and its in vitro correction by interleukin 2. J Clin Immunol 3:332-340, 1983

59.

Kirkpatrick CH , Davis KC , Horsburgh CR Jr , et al: Interleukin-2 production by persons with the generalized lymphadenopathy syndrome or the acquired immune deficiency syndrome. J Clin Immunol 5:31-37, 1985

60.

Lane HC , Siegel JP , Rook AH , et al: Use of interleukin-2 in patients with acquired immunodeficiency syndrome. J Biol Response Mod 3:512-516, 1984

61.

Ellis RW : New technologies for making vaccines, in Plotkin SA , Mortimer EA Jr (eds): Vaccines. Philadelphia, PA, Saunders , 1988, pp 568-575

62.

Fields BN , Chanock RM : What biotechnology has to offer vaccine development. Rev Infect Dis 11:s519-523, 1989 (suppl 3)

63.

Zavala F. , Tam JP , Hollingdale MR , et al: Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science 228:1436-1440, 1985

64.

Herrington DA , Clyde DF , Losonsky G. , et al: Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites . Nature 328:257-259,1987

65.

Center for Disease Control, ACIP : Update on hepatitis B prevention. MMWR 36:353-366, 1987

66.

Center for Disease Control, ACIP : Protection against viral hepatitis. MMWR 39:1-26, 1990

67.

Zahradnik JM , Couch RB , Gerin JL : Safety and immunogenicity of a purified hepatitis B virus vaccine prepared by using recombinant DNA technology. J Infect Dis 155:903-908, 1987

68.

Goudeau A. , Denis F. , Mounier M. , et al: Comparative multicentre study of the immunogenicity of different hepatitis B vaccines in healthy volunteers. Postgrad Med J 63:125-128,1987 (suppl 2)

69.

Just M. , Berger R. , Just V. : Reactogenicity and immunogenicity of a recombinant hepatitis B vaccine compared with a plasma-derived vaccine in young adults. Postgrad Med J 63:121-123, 1987 (suppl 2)

70.

Almond JW , Cann AJ : Attenuation, in Roitt IM (ed): Immune Intervention: New Trends in Vaccines. San Diego, CA, Academic, 1984, pp 13-56

71.

Levine MM , Kaper JB , Herrington D. , et al: Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet 2:467-470, 1988

72.

Paoletti E. , Perkus ME , Piccini A. , et al: Vaccinia vectored vaccines, in Quinnan, GV Jr (ed): Vaccinia viruses as vectors for vaccine antigens. New York, NY, Elsevier , 1985, pp 137-151

73.

Lambert PH : Anti-idiotypic vaccines, in Bell R , Torrigiani G (eds): Progress towards better vaccines. New York, NY, Oxford University Press on behalf of the World Health Organization, 1986, pp 89-96